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Background: Kidney injury molecule-1 (KIM-1) is a biomarker useful for detecting early tubular damage and has
been recently reported as a useful marker for evaluating kidney injury in IgA nephropathy (IgAN). We therefore
investigated whether treatment decreases urinary KIM-1 excretion in IgAN.
Methods: We prospectively enrolled 37 patients with biopsy-proven IgAN. Urinary KIM-1 was assessed before and
after treatment, which included low salt diet, blood pressure control, pharmacotherapy with angiotensin receptor
blockers and/or angiotensin converting enzyme inhibitors, and immunosuppressive agents as necessary. The
median treatment duration was 24 months.
Results: Urinary KIM-1/creatinine (Cr) was significantly decreased in patients with IgAN after treatment compared to
baseline (P < 0.0001, 1.16 [0.51-1.83] vs 0.26 [0.12-0.65] ng/mg). There was a decrease in the amount of proteinuria after
treatment, but it was not statistically significant (P = 0.052, 748.1 [405-1569.7] vs 569.2 [252.2-1114] g/d). Estimated
glomerular filtration rate (eGFR) did not change with treatment (P = 0.599, 79.28 ± 30.56 vs 80.98 ± 32.37 ml/min/
1.73 m2). Urinary KIM-1 was not correlated with proteinuria baseline or follow up (pre-: R = - 0.100, P = 0.577,
post-: R = 0.001, P = 0.993). In patients with higher baseline urinary KIM-1, both urinary KIM-1 level and
proteinuria were significantly decreased following treatment.
Conclusions: Treatment decreases urinary KIM-1/Cr in patients with IgAN. It also reduces proteinuria in patients
with higher baseline urinary KIM-1. These results suggest a potential role for urinary KIM-1 as a biomarker for
predicting treatment response in IgAN, however, further study is needed to verify this.
Keywords: Biomarker, IgA nephropathy, KIM-1, Treatment in IgA nephropathy reduced the urinary KIM-1
excretionBackground
IgA nephropathy (IgAN) is the most common glomerulo-
nephritis in the world, accounting for 20-45% of primary
glomerular disease [1,2]. Long-term studies report that up
to 30% of patients with IgAN progress to end-stage renal
disease (ESRD) within twenty years [3-5]. Hypertension,
massive proteinuria, elevated serum creatinine concentra-
tion, glomerular sclerosis, and interstitial fibrosis are pre-
dictors of poor renal outcome in IgAN [4,5]. However,
these prognostic indicators have low sensitivity and* Correspondence: ksoonhyo@schmc.ac.kr
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reproduction in any medium, provided the orspecificity [6]. More accurate prognostic markers are re-
quired to predict the progress of IgAN and determine
treatment.
Kidney injury molecule-1 (KIM-1) is a sensitive marker
for detecting the presence of tubular damage [7-10]. KIM-
1 expression is significantly induced in various primary
and secondary kidney diseases and in allograft nephropa-
thy [9-11]. Tubular KIM-1 expression is significantly asso-
ciated with tubulointerstitial injury and inflammation, and
increased urinary KIM-1 levels are strongly related to
tubular KIM-1 expression [8,10,11]. Therefore, urinary
KIM-1 is a valuable biomarker for the existence of
tubulointerstitial damage.
Recent studies have shown that in patients with IgAN,
urinary KIM-1 is closely associated with disease severity. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics at baselinea
Characteristic
Age (years) 39.18 ± 11.57
Male/Female (n){%} 18/19 {48.6/51.4}
Serum Creatinine (mg/dL) 1.24 ± 0.68
CKD EPI eGFR (ml/min/1.73 m2) 79.28 ± 30.56
24 hr Urinary Protein (mg/day) 748.1 [405-1569.7]
Mean Blood Pressure, systolic (mmHg) 125.4 ± 13.8
Mean Blood Pressure, diastolic (mmHg) 78.1 ± 8.7
Mesagial hypercellularity (%) 64.8
Segmental glomerulosclerosis (%) 91.8
Endocapillary hypercellularity (%) 37.8
Tubular atrophy/interstitial fibrosis 1 (%) 32.4
Tubular atrophy/interstitial fibrosis 2 (%) 21.6
aData are expressed as mean ± SD or median with interquartile range.
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ever, it is still unclear whether urinary KIM-1 levels are
affected by treatment. In the current study, we investi-
gated whether urinary excretion of KIM-1 changes after
treatment in patients with IgAN. We then further ana-




For the present study, prospective patients with biopsy-
proven IgAN were enrolled from January 2009 at Soon
Chun Hyang University Seoul and Bucheon Hospital.
Study protocols were reviewed and approved by the
Soon Chun Hyang University Seoul Hospital Institu-
tional Review Board and Soon Chun Hyang University
Bucheon Hospital Institutional Review Board, and writ-
ten informed consent was obtained from each patient
before enrollment. A diagnosis of IgAN was defined as
the predominant mesangial deposition of IgA. Clinical
and laboratory data were collected at the time of biopsy.
Urinary samples were centrifuged at 3000 rpm for
10 min to remove cellular components, and the super-
natant was frozen at -70°C until use. Urinary KIM-1 ex-
cretion was measured at diagnosis. Urinary KIM-1 was
then measured at follow-up after about 2 years of treat-
ment that included a low salt diet, blood pressure control,
pharmacotherapy with angiotensin receptor blockers and/
or angiotensin converting enzyme inhibitors, and im-
munosuppressive agents as necessary. All patients were
treated with angiotensin receptor blockers (ARB) and/or
angiotensin converting enzyme inhibitors (ACEi). Steroid
pulse therapy and oral prednisolone was administered to
patients with sustained massive protein excretion exceed-
ing 2 g/day. Patients with other causes of IgA-positive
glomerular staining (systemic lupus erythematosus,
Henoch-Schönlein purpura, or liver disease) were ex-
cluded from the analysis.
Detection of urinary KIM-1 by enzyme-linked
immunossorbent assay
ELISA was performed in duplicate using a commercial kit
(R&D System, MN, USA) in accordance with the manufac-
turer’s guidelines to measure KIM-1 protein levels in the
urine. Inter- and intra-assay variability was <10%. To adjust
urinary KIM-1 levels, urinary creatinine was also measured
for each urine specimen. Adjusted urinary KIM-1 was
expressed as urinary KIM-1concentration/creatinine con-
centration (ng/mg Cr). All KIM-1 levels in this study
are expressed in this way. Reference values for urinary
KIM-1/creatinine were obtained from urine measure-
ments in 27 healthy volunteers who were all unmatched
Korean men and women. Mean urinary KIM-1 excretion
was 0.18 ng/mg with a 95% confidence interval (CI) of0.096 to 0.27 ng/mg. The cutoff value for normal
(0.27 ng/mg) was based on the upper limit of the 95% CI.
The urinary KIM-1 of IgAN patients increased compared
to that of normal volunteers [14].
Grading of tubular atrophy/interstitial fibrosis
Grading of tubular atrophy/interstitial fibrosis followed
the Oxford classification system, in which grading is de-
termined by the percentage of cortical area involved by
tubular atrophy or interstitial fibrosis, whichever is
greater (tubular atrophy/interstitial fibrosis 0: 0-25%,
tubular atrophy/interstitial fibrosis 1: 26-50%, tubular at-
rophy/interstitial fibrosis 2: > 50%) [15].
Statistical analyses
Data are expressed as mean ± standard deviation or as
median with interquartile range. Differences in quantita-
tive data were evaluated using a paired t-test. Differences
in qualitative data were evaluated using a chi-square test.
When a normal distribution was present, ANOVA with
a post hoc test or paired t-test were used. When an ab-
normal distribution was present, the nonparametric
Kruskal-Wallis and Wilcoxon signed rank tests were
used. Correlations between urinary KIM-1 and clinical
parameters were determined using the Pearson correl-
ation coefficient. P-values of <0.05 were considered sta-
tistically significant. Statistical analysis was performed
using SPSS for Windows software version 14.0 (SPSS
Inc., Chicago, IL, USA).
Results
Clinical and histopathological characteristics of patients
with IgAN
Thirty-seven patients with IgAN were studied. Patient
characteristics at baseline are presented in Table 1.
Table 2 Clinical characteristics according to treatment modalitya
Variable Immunotherapy No imunotherapy P
Age (years) 33.6 ± 18.32 40.06 ± 10.31 0.481
Male/Female {%} 4/1 {80/20} 15/17 {47/53} <0.0001
Serum Creatinine (mg/dL) 1.52 ± 0.55 1.20 ± 0.69 0.347
CKD EPI eGFR (ml/min/1.73 m2) 70.06 ± 37.03 80.62 ± 29.90 0.505
24 hrs Urinary Protein (mg/day) 4077.18 ± 3098.19 1000.63 ± 899.85 <0.0001
Mean Blood Pressure, systolic (mm/Hg) 128 ± 13 125 ± 14.14 0.693
Mean Blood Pressure, diastolic (mmHg) 76 ± 8.3 78 ± 8.95 0.664
Mesagial hypercellularity (%) 100 59.4 <0.0001
Segmental glomerularsclerosis (%) 100 90.7 <0.0001
Endocapillary hypercellularity (%) 80 31.3 <0.0001
Tubular atrophy/interstitial fibrosis 1 (%) 0 37.5 <0.0001
Tubular atrophy/interstitial fibrosis 2 (%) 60 15.7 <0.0001
Baseline KIM-1/Cr (ng/mg) 0.51 [0.31-1.23] 1.12 [0.62-2.02] 0.155
Follow-up KIM-1/Cr (ng/mg) 0.52 [0.01-0.64] 0.26 [0.13-0.73] 0.625
Δ KIM-1/Cr (ng/mg) 0.49 [0.34-0.71] 0.81 [0.17-1.23] 0.230
Baseline eGFR (ml/min/1.73 m2) 70.65 ± 37.03 80.62 ± 29.9 0.505
Follow-up eGFR (ml/min/1.73 m2) 72.82 ± 48.44* 82.26 ± 30.03** 0.552
Baseline proteinuria (mg/d) 4855.1 [1569.7-5560.5] 720 [401-1189.7]
Follow-up proteinuria (mg/d) 1323.9 [374.6-1480] 545.6 [250.5-824]
P 0.273 0.077
aData are expressed as median ± SD or median with interquartile range.
Compared with baseline eGFR: *P = 0.904; **P = 0.572.
Figure 1 Comparison of baseline and follow-up urinary
KIM-1/Cr (ng/mg).
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During follow up, all patients were treated with ACEis and/
or ARBs. Immunosuppressive therapy was initiated in five
patients (13.5%) who either had progressive deterioration of
renal function or persistent proteinuria (Table 2). A com-
parison of the clinical and histopathological characteristics
of the patients receiving and not receiving immunosuppres-
sive therapy is shown in Table 2. 24 hr urinary protein was
significantly higher in the immunosuppressive therapy group
(P < 0.01, 4.07 ±3.09 vs 1.00 ± 0.89 g/d). The propor-
tion of patients with mesangial hypercellularity, seg-
mental glomerulosclerosis, endocapillary hypercellularity,
and tubular atrophy/interstitial fibrosis 2 was significantly
higher in the immunosuppressive therapy group.
Concentration of urinary KIM-1 at baseline and follow-up
The mean follow up duration was 23.56 ± 5.08 months.
Baseline urinary KIM-1 was 1.16 [0.51-1.83] ng/mg
while the follow-up level was 0.26 [0.12-0.65] ng/mg.
Urinary KIM-1 was significantly decreased in patients
with IgAN after treatment (Figure 1). KIM-1 levels nor-
malized in 19 patients (51.35%) after treatment.
Clinical parameters of IgAN patients at baseline and follow-up
At follow-up, there was a decrease in the amount of pro-
teinuria, but it was not statistically significant (P = 0.052,748.1 [405-1569.7] vs 569.2 [252.2-1114] g/d). Treatment
did not affect estimated glomerular filtration rate (eGFR)
(P = 0.599, 79.28 ± 30.56 vs 80.98 ± 32.37 ml/min/1.73 m2)
(Table 3).
Although we found that proteinuria was not significantly
reduced after treatment, this was not the case when we an-
alyzed treatment response in patients stratified according
to tertiles of baseline urinary KIM-1. After treatment, urin-
ary KIM-1 and proteinuria were significantly decreased in
Table 3 Comparison of baseline and follow-up clinical
parametersa
Variable Baseline Follow-up P
Serum Creatinine (mg/dL) 1.0 [0.9-1.3] 1.0 [0.8-1.3] 0.542
CKD EPI eGFR
(ml/min/1.73 m2)
79.28 ± 30.56 80.98 ± 32.37 0.599
SBP (mmHg) 125 ± 13.86 119 ± 15.97 0.050
DBP (mmHg) 78 ± 8.76 74 ± 10.68 0.080
24 hrs Urinary
Protein (mg/day)
748.1 [405-1569.7] 569.2 [252.2-1114] 0.052
aData are expressed as median ± SD or median with interquartile range.
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proteinuria: P = 0.01) (Table 4).
When comparing patients whose KIM-1 levels did and
did not normalize following treatment, there was no sig-
nificant decrease of proteinuria or eGFR in either group.
There was also no significant difference in follow-up
proteinuria or eGFR between the two groups (Table 5).
We also compared proteinuria and eGFR between pa-
tients who did and did not receive immunosuppressive
therapy. There was no significant decrease in proteinuria
or eGFR in either group after treatment (Table 2).
Finally, we analyzed proteinuria and eGFR according
to reduction of 24 hr urinary protein. There was no sig-
nificant difference in baseline or follow-up KIM-1 be-
tween patients whose 24 hr urinary protein did and did
not decrease by more than 50%. However, there was a
significant difference in follow-up eGFR between the
two groups (P = 0.04) (Table 6).
In our study, baseline urinary KIM-1 was not corre-
lated with renal KIM-1 grade or Oxford classification of
renal damage [14].
Association between urinary KIM-1 and proteinuria
Urinary KIM-1 was not correlated with proteinuria at
baseline or follow-up (baseline: R = 0.100, P = 0.577,
follow-up: R = 0.001, P = 0.993).
Discussion
Interstitial kidney damage is a consistent predictor of renal
prognosis. Several studies have identified clinical features
and histological findings which serve as predictors ofTable 4 Treatment response stratified by baseline urinary KIM
n = 13
Baseline KIM-1/Cr (ng/mg) 0.39 [0.3-0.51]
Follow-up KIM-1/Cr (ng/mg) 0.26 [0.12-0.61]
P 0.91
Baseline proteinuria (mg/d) 1109 [528.2-1639]
Follow-up proteinuria (mg/d) 722.1 [252.2-1323.9]
p 0.333
aData are expressed as median with interquartile range.adverse renal outcomes. In particular, tubulointerstitial
changes have been recognized as important prognostic
factors in IgAN [16-19]. However, tubulointerstitial dam-
age is not always associated with proteinuria, which is a
marker of glomerular damage [20]. Therefore, it is import-
ant to identify a biomarker specific for tubular damage to
accurately monitor therapy response and tubular damage
in IgAN.
Our data showed that IgAN treatment significantly de-
creased urinary KIM-1 concentration. This finding sug-
gests that urinary KIM-1 may be a useful biomarker for
evaluating and predicting treatment response. Previous
studies have found that KIM-1 expression in proximal
tubules is associated with interstitial fibrosis and inflam-
mation in various renal diseases [10,11]. Several studies
have reported that urinary KIM-1 levels are correlated
with tubular KIM-1 expression in experimental models
and human renal disease [8-10,21]. Because of this, and
because it is a non-invasive marker for kidney damage,
KIM-1 is a promising biomarker. In IgAN, urinary KIM-1
has clinical implications in predicting renal outcome and
assessing tubulointerstitial damage [12,13]. Waanders
et al. have reported that urinary KIM-1 levels decreased
following antiproteinuric treatment in non-diabetic pa-
tients. However, this study included only a small number
of IgAN patients (n = 5) and had a relatively short follow
up duration (6 weeks) [20]. Because IgAN is the most
common glomerulonephritis in the world, KIM-1 should
be verified as a therapeutic parameter with a long-term
study in a large IgAN cohort.
We treated biopsy-proven IgAN patients using con-
ventional methods for 24 months, which resulted in a
decrease in KIM-1. We believe there are several possible
mechanisms for this result. First, treatment can reverse
interstitial damage. All patients were treated with at least
one RAS antagonist. One observational human study
reported that treatment with an ARB can improve renal
interstitial fibrosis. In that study, patients with biopsy-
proven IgAN and non-IgA mesangioproliferatve glomer-
ulonephritis were treated with an ARB for an average of
28 months. Although the global sclerosis ratio was not
significantly altered by treatment with an ARB, 13 of the
15 patients showed decreases in mesangial matrix and-1 levela
n = 12 n = 12
1.19 [1.02-1.28] 2.59 [1.94 -3.7]
0.17 [0.09-0.4] 0.62 [0.22-1.35]
0.002 0.008
537.5 [296.9-1453.2] 916.5 [508.2-1262.2]
509.5 [237.2-979.6] 518.3 [361.8-766]
0.678 0.018
Table 5 Baseline and follow-up clinical parameters according to normalization of urinary KIM-1a
Patients with normalization (n = 19) Patients without normalization (n = 18) P
Baseline proteinuria (mg/d) 718 [348.3–1417] 1006.25 [537.1-2269.9]
Follow-up proteinuria (mg/d) 522 [868.4-1114]* 572.65 [270-1260.7]** 0.871
Baseline eGFR (ml/min/1.73 m2) 88.6 ± 36.2 72.6 ± 29.4
Follow-up eGFR (ml/min/1.73 m2) 78.3 ± 34# 83.8 ± 31.2& 0.283
a Data are expressed as median ± SD or median with interquartile range.
Compared with baseline proteinuria: *P = 0.925; **P = 0.11.
Compared with baseline eGFR: #P = 0.334; &P = 0.141.
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with an ARB reversed tubular Kim-1 expression in an
adriamycin induced nephropathy model [21]. In several
other experimental models, ARBs produced renal struc-
tural improvement [23-25]. These studies suggest that
RAS blockade can improve tubulointerstital damage and
decrease urinary Kim-1, a marker of tubular damage.
Another explanation for the decreased KIM-1 is that a
reduction in proteinuria can lower urinary KIM-1 excre-
tion. A recent study showed that tubular expression of
Kim-1 decreased in proportion to decreases in proteinuria
as a result of RAAS blockade in adriamycin induced ne-
phropathy and homozygous Ren2rats [21,26]. Another
study found proteinuria was able to cause tubulointerstital
injury [27]. These studies support the hypothesis that de-
creased proteinuria reduces proteinuria-induced tubular
damage and decreases Kim-1 expression.
A previous study involving patients with various renal
diseases showed that even when proteinuria was reduced
below a certain threshold (less than 1 g/d), urinary KIM-
1 did not normalize in 14 of 16 patients [20]. Although
our treatment did not profoundly decrease proteinuria,
KIM-1 did reach the normal range in 50% of patients. In
patients in the highest tertile for baseline KIM-1, urinary
KIM-1 and proteinuria were significantly decreased after
treatment. Previous studies reported Kim-1 was not
detected in severely damaged tubules [10,14,21]. As tubular
KIM-1 expression is specific to ongoing tubular cell dam-
age and differentiation [28,29], we hypothesized urinary
KIM-1 represented reversibility. In an experimental model,
Kim-1 expression was reduced in proportion to proteinuric
reduction [21]. This supports the potential of KIM-1 as a
biomarker for tubulointerstitial damage and repair.Table 6 Baseline and follow-up clinical parameters according
Variable Proteinuria reduction > 50% (
Baseline KIM-1/Cr (ng/mg) 1.17 [0.44-1.91]
Follow-up KIM-1/Cr (ng/mg) 0.41 [0.21-0.74]
Baseline eGFR (ml/min/1.73 m2) 87.86 ± 30.34
Follow-up eGFR (ml/min/1.73 m2) 98.78 ± 27.86
aData are expressed as median ± SD or median with interquartile range.In our study, treatment reduced urinary KIM-1, but this
was not accompanied by a reduction in other clinical pa-
rameters. The progression of IgAN is slow, and the re-
sponse to treatment is also slow. In this study, the
follow-up period was relatively short. The proteinuria
reduction for all patients did not reach statistical sig-
nificance, however, it showed a trend in that direction
(p = 0.053). The antecedent reduction of urinary KIM-
1 suggests that urinary KIM-1 may be a more sensitive
biomarker and has unique clinical implications in
IgAN. KIM-1 has been reported as a better independ-
ent prognostic marker than proteinuria for IgAN [12].
Although proteinuria has been considered a main risk fac-
tor for decreased kidney function, this is an inconsistent
conclusion [6,30,31]. Therefore, long-term studies are
needed to evaluate whether treatments targeting KIM-1
can improve outcomes in patients with IgAN.
The correlation between urinary KIM-1 and protein-
uria is also inconsistent [8,10,32]. Differences in urinary
KIM-1 measurement methods may be cause this dis-
crepancy. Preclinical KIM-1 assays should be validated
in a large cohort and a variety of clinical settings. Re-
cently, a number of urinary biomarkers have emerged
for kidney disease. These urinary biomarkers have the
potential to facilitate early diagnosis and management of
kidney damage. They may be able to alert clinicians to
kidney damage before it can be identified using conven-
tional measurements, such as change in glomerular fil-
tration rate or proteinuria. It is therefore necessary to
verify the usefulness of KIM-1 by conducting a long-
term study in a large population. This will determine
whether treatments targeting KIM-1 can improve out-
come in patients with chronic kidney disease.to reduction in 24 hr urinary proteina
n = 10) Proteinuria reduction < 50% (n = 26) P
1.16 [0.57-1.62] 0.811
0.19 [0.11-0.64] 0.393
76.1 ± 30.59 0.305
74.39 ± 31.87 0.040
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small number of patients who have well preserved renal
function. This population does not represent the various
stages of IgAN. Second, the ELISA method used in our
study has limited sensitivity. However, the sensitivity was
sufficient to investigate the association between urinary
KIM-1 and clinical parameters in patients with IgAN.
Lastly, because of difficulties in obtaining repeat biop-
sies, we cannot conclude that decreases in the concen-
tration of urinary KIM-1 improve renal outcomes in
IgAN.
Conclusions
Treatment decreases urinary KIM-1/Cr in patients with
IgAN. Urinary KIM-1 does not correlate with protein-
uria. Treatment reduced proteinuria in patients in the
highest tertile for baseline KIM-1. Future studies should
be undertaken to verify the usefulness of KIM-1 as bio-
marker in IgAN.
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